José Trevejo

Visterra, Inc. Is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antibody-based therapies for kidney diseases, and other chronic diseases. It focuses on its research technology platform, HIEROTOPE technology. The company was founded by Alan L. Crane, Kevin J. Bitterman and Ram Sasisekharan on December 20, 2007 and is headquartered in Waltham, MA.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Vertex Pharmaceuticals (Canada), Inc. operates as a biotechnology company that invests in scientific innovation to create medicines for people with serious and life-threatening diseases. It discovered medicines to treat the cause of cystic fibrosis a genetic disease. The company is headquartered in Toronto, Canada.

The Charles Stark Draper Laboratory, Inc. engages in the design, development, and deployment of technological solutions. It focuses on the areas of commercial, space, national security, strategic systems, and global challenges. It provides engineering services to government, commercial companies, and educational institutions. The company was founded by Charles Stark Draper in 1934 and is headquartered in Cambridge, MA.

Diabetes Hands Foundation is non profit organization which provides support and medical assistance for diabetes. It offers programs that provide social support information, promote diabetes awareness, and improves the lives of people living with diabetes. The company is headquartered in Berkeley, Canada.

SmartPharm Therapeutics, Inc. engages in the development of next-generation, non-viral gene therapies for the treatment of serious or rare diseases. Its pipeline include Gene MAbs for SARS-Cov-2, enzyme replacement therapy, and cell and tissue restoration. The company was founded by José Trevejo in 2017 and is headquartered in Cambridge, MA.